Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE MLV & Co
Dr. Arlinda Lee and Dr. George Zavoico Join MLV & Co as Senior Healthcare Analysts
NEW YORK, May 20, 2014 /PRNewswire/ -- MLV & Co announced today that Arlinda Lee, Ph.D. and George Zavoico, Ph.D. have joined the firm's growing healthcare research team as senior analysts. Dr. Lee was previously at Barclays, Bear Stearns, and CRT, while Dr. Zavoico rejoins the firm after a brief hiatus. Both senior analysts will work out of the firm's New York office and focus on the rapidly growing Healthcare and Biotechnology sectors.
"Recruiting two highly regarded and knowledgeable analysts like Dr. Lee and Dr. Zavoico represents another example of MLV & Co's commitment to build the best and biggest Healthcare platform on Wall Street," said Patrice McNicoll, CEO and founding partner of MLV & Co. "They will further expand our already deep bench in this sector."
"We are very excited to add Dr. Lee and Dr. Zavoico to our Healthcare research team," said Dean Colucci, President of MLV & Co. "Their broad individual experiences in all phases of the industry, combined with their uncanny ability to clearly communicate the financial impact of complex scientific data, furthers our goal of providing the most relevant research to our clients."
Dr. Lee has more than ten years of experience as a senior analyst covering Biotechnology, with expertise in fundamental research and pipeline assessments across therapeutic areas. Prior to joining MLV & Co, Dr. Lee worked at CRT Capital Group as a Lead Biotechnology Analyst. Dr. Lee's experience also includes covering a broad range of Biotechnology companies for Barclays, FTN Equity Capital Markets, and Bear, Stearns & Co. Inc. Dr. Lee holds a Ph.D. in Genetics from the Cold Spring Harbor Laboratory of Stony Brook University and a B.A. in Molecular and Cell Biology and B.A. in Rhetoric from U.C. Berkley where she was a John Mills Gayley Fellow.
Dr. Zavoico has more than ten years of experience as a life sciences equity analyst writing research on publicly traded equities. Prior to returning to MLV & Co, where he helped establish its Healthcare research team in 2010, Dr. Zavoico worked briefly at H.C. Wainwright & CO. as a Senior Analyst. Dr. Zavoico's prior experience includes work as an equity research analyst for Cantor Fitzgerald. He began his career as a Senior Research Scientist at Bristol-Meyers Squibb Co., moving on to management positions at Alexion Pharmaceuticals, Inc. and T Cell Sciences, Inc. (now Celldex Therapeutics, Inc.). Dr. Zavoico holds a Ph.D. in Physiology from the University of Virginia and a B.S. in Biology from St. Lawrence University.
About MLV & Co:
An independent full service investment bank and institutional broker dealer, MLV & Co is focused on creative capital raising solutions to growth-oriented companies in healthcare, real estate, financials, energy & natural resources, and other "capital-intensive" sectors. Since its inception in 2010, MLV & Co has completed more than 175 transactions and raised more than $8 billion on behalf of its clients. MLV & Co has also been the market leader in ATM transactions since its inception. From 2010 through the present, MLV has been the lead underwriter on over 140 ATMs totaling over $4 billion in notional value, surpassing every other investment bank during this period. MLV is a member of FINRA, NASDAQ, and the SIPC.
MLV & Co News Alerts
Dukas Public Relations
©2012 PR Newswire. All Rights Reserved.